The FDA’s accelerated approval of GENGLYCOS™ (pariglasgene brecaparvovec-opnr), also known as DTX401, introduces the first FDA-approved treatment option for glycogen storage disease type Ia (GSDIa).

Hospital contracting is a critical element for health plans because it dictates the plan's financial viability, price predictability, and market competitiveness.